LYTIR

Company · OCUL

Ocular Therapeutix, Inc.

Name as listed on its exchange; filed with the SEC as OCULAR THERAPEUTIX, INC.

Nasdaq's symbol directory lists OCUL on Nasdaq as “Ocular Therapeutix, Inc. - Common Stock”.

In the 12 months to Nov 19, 2026: insiders sold on 9 occasions ($799K); 4 planned-sale notices; 3 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC · Appeared in No. 45

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $799K in total.Aug: Insider sales $333KOct: Insider sales $234KNov: Insider sales $232KDecJanFebMarAprMayJunJulAugSepOctNov$333K
Insider purchases above the line: $0Insider sales below: $799K
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Dugel Pravin, Executive Chairman, President and CEO sold on 1 day all under a 10b5-1 plan latest Aug 24, 2026 sold $233K
  2. Saroj Namrata, Chief Business Officer sold on 1 day all under a 10b5-1 plan latest Nov 5, 2026 sold $232K
  3. Heier Jeffrey S., Chief Scientific Officer sold on 2 days all under a 10b5-1 plan latest Oct 2, 2026 sold $112K
  4. Kaiser Peter, Chief Development Officer sold on 2 days all under a 10b5-1 plan latest Oct 2, 2026 sold $103K
  5. Anderman Todd, Chief Legal Officer sold on 1 day all under a 10b5-1 plan latest Oct 8, 2026 sold $87K
  6. Nayak Sanjay, Chief Strategy Officer sold on 1 day all under a 10b5-1 plan latest Aug 24, 2026 sold $20K
  7. Notman Donald, Chief Operating Officer sold on 1 day latest Aug 31, 2026 sold $11K
Every trade (9)
  1. SELLSaroj Namrata, Chief Business Officer sold Nov 5, 2026 35,370 shares 10b5-1 plan (scheduled) filing $232K
  2. SELLAnderman Todd, Chief Legal Officer sold Oct 8, 2026 11,984 shares 10b5-1 plan (scheduled) filing $87K
  3. SELLHeier Jeffrey S., Chief Scientific Officer sold Oct 2, 2026 10,869 shares 10b5-1 plan (scheduled) filing $77K
  4. SELLKaiser Peter, Chief Development Officer sold Oct 2, 2026 9,990 shares 10b5-1 plan (scheduled) filing $70K
  5. SELLNotman Donald, Chief Operating Officer sold Aug 31, 2026 1,099 shares filing $11K
  6. SELLDugel Pravin, Executive Chairman, President and CEO sold Aug 24, 2026 21,649 shares 10b5-1 plan (scheduled) filing $233K
  7. SELLHeier Jeffrey S., Chief Scientific Officer sold Aug 24, 2026 3,296 shares 10b5-1 plan (scheduled) filing $36K
  8. SELLKaiser Peter, Chief Development Officer sold Aug 24, 2026 3,035 shares 10b5-1 plan (scheduled) filing $33K
  9. SELLNayak Sanjay, Chief Strategy Officer sold Aug 24, 2026 1,897 shares 10b5-1 plan (scheduled) filing $20K

Planned sales · SEC Form 144

Notice given

A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice

  1. NAMRATA SAROJ filed Nov 5, 2026 Officer 35,370 shares planned sale date 11/05/2026 filing $232K
  2. TODD ANDERMAN filed Oct 8, 2026 Officer 11,984 shares planned sale date 10/08/2026 filing $87K
  3. JEFFREY S. HEIER filed Oct 2, 2026 Officer 10,869 shares planned sale date 10/02/2026 filing $77K
  4. PETER KAZUO KAISER filed Oct 2, 2026 Officer 9,990 shares planned sale date 10/02/2026 filing $70K

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Departure or appointment of directors or officers filing Nov 9, 2026
  2. Results of operations and financial condition filing Nov 9, 2026
  3. Departure or appointment of directors or officers filing Oct 16, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.